https://www.nrgtherapeutics.com/nrg-therapeutics-announces-first-participants-dosed-in-its-first-in-human-phase-1-clinical-trial-of-nrg5051-which-is-being-developed-as-a-disease-modifying-treatment-for-als-mnd-and-parkinson/2026-07-31T12:02:19+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-announces-further-expansion-with-the-appointment-of-paul-thompson-as-chief-development-officer/2026-07-31T12:02:23+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-announces-senior-appointments-as-it-advances-nrg5051-towards-first-in-human-clinical-studies/2026-09-10T13:57:33+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-announces-oversubscribed-50m-67m-series-b-financing-to-deliver-clinical-data-in-parkinsons-and-proof-of-concept-in-als-mnd/2026-07-31T12:02:30+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-selects-first-development-candidate-nrg5051-and-secures-grant-from-the-michael-j-fox-foundation-for-development-of-mptp-inhibitors-to-treat-neurodegenerative-diseases/2026-09-10T13:58:41+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-awarded-grant-funding-from-target-als-to-support-the-development-of-mptp-inhibitors-as-novel-treatments-for-als-mnd/2026-07-31T12:11:57+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-appoints-dr-jonathan-savidge-as-independent-chair/2026-09-10T14:01:10+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-appoints-vad-lazari-ph-d-as-vice-president-of-biology-to-advance-its-mitochondrial-therapeutics-for-neurodegenerative-disorders/2026-07-31T12:21:39+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-announces-international-scientific-advisory-board/2026-09-10T14:02:40+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-awarded-second-500k-grant-from-the-michael-j-fox-foundation-to-further-progress-parkinsons-programme/2026-07-31T12:29:11+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-appoints-gilles-ouvry-ph-d-as-vice-president-of-chemistry-to-advance-its-mitochondrial-therapeutics-for-neurodegenerative-disorders/2026-07-31T12:31:59+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-announces-16-million-series-a-to-advance-mitochondrial-therapeutics-for-parkinsons-and-als/2026-07-31T12:32:48+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-selects-domainex-to-be-its-integrated-drug-discovery-partner-for-its-biomedical-catalyst-funded-parkinsons-disease-project/2026-09-10T14:03:29+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-announces-2-68m-innovate-uk-award-to-develop-new-medicines-to-treat-parkinsons-and-motor-neurone-disease/2026-09-10T14:04:49+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-completes-mnd-therapeutic-analysis-project-with-medicines-discovery-catapult-supported-by-an-innovate-uk-edge-grant/2026-07-31T12:36:03+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-launches-mnd-drug-discovery-programme-and-announces-new-collaboration-in-australia/2026-07-31T12:37:52+01:00https://www.nrgtherapeutics.com/parkinsons-uk-invests-a-further-490k-in-nrg-therapeutics-to-progress-parkinsons-drug-discovery-programme/2026-07-31T12:38:37+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-awarded-500k-grant-from-the-michael-j-fox-foundation-to-progress-parkinsons-programme/2026-07-31T12:39:21+01:00https://www.nrgtherapeutics.com/parkinsons-uk-continues-drug-discovery-with-nrg-therapeutics-ltd/2026-07-31T12:40:50+01:00https://www.nrgtherapeutics.com/dr-richard-seabrook-joins-board-of-nrg-therapeutics/2026-07-31T12:42:56+01:00https://www.nrgtherapeutics.com/charity-invests-1-million-to-develop-a-treatment-to-slow-down-progression-of-parkinsons/2026-07-31T12:42:27+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-ceo-spotlight-video-sbc/2026-08-14T11:19:05+01:00https://www.nrgtherapeutics.com/als-nexus-conference-2026/2026-09-11T14:22:41+01:00https://www.nrgtherapeutics.com/scrip-asks-what-does-2026-hold-for-biopharma-part-4-rd-innovation/2026-08-14T14:55:55+01:00https://www.nrgtherapeutics.com/founder-ceo-interview-series/2026-08-14T11:19:20+01:00https://www.nrgtherapeutics.com/disease-modifying-treatment-for-als-enters-phase-i/2026-08-14T13:36:48+01:00https://www.nrgtherapeutics.com/target-als-grantee-nrg-therapeutics-advances-nrg5051-into-phase-i-clinical-trial/2026-08-14T11:36:51+01:00https://www.nrgtherapeutics.com/target-als-grantee-nrg-therapeutics-advances-nrg5051-into-phase-i-clinical-trial-target-als/2026-08-14T12:44:40+01:00https://www.nrgtherapeutics.com/nrg-doses-first-volunteers-in-mitochondrial-als-trial/2026-08-14T12:48:43+01:00https://www.nrgtherapeutics.com/michael-j-fox-foundation-adviser-joins-nrg-therapeutics/2026-08-14T13:36:04+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-expands-team-with-cdo-appointment/2026-08-14T12:54:04+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-appoints-paul-thompson-as-cdo/2026-08-14T12:55:39+01:00https://www.nrgtherapeutics.com/uk-life-sciences-future50-momentum-in-an-evolving-landscape/2026-09-09T17:39:23+01:00https://www.nrgtherapeutics.com/11-neuroscience-biotech-companies-you-should-know-about/2026-08-14T12:58:40+01:00https://www.nrgtherapeutics.com/is-this-mitochondrias-big-moment/2026-08-14T13:17:25+01:00https://www.nrgtherapeutics.com/biotechs-bia-patient-charities-and-investors-the-power-of-relationships/2026-08-14T13:18:35+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-restoring-motor-neuron-function-via-mitochondria/2026-09-09T17:38:56+01:00https://www.nrgtherapeutics.com/nrg-raises-67m-to-test-mitochondrial-pore-inhibitor-in-als/2026-09-09T17:39:46+01:00https://www.nrgtherapeutics.com/a-uk-biotech-takes-aim-at-parkinsons-als-by-drugging-mitochondria/2026-08-14T13:52:49+01:00https://www.nrgtherapeutics.com/uks-nrg-powers-up-with-50m-for-promising-mitochondrial-therapy/2026-09-09T17:40:02+01:00https://www.nrgtherapeutics.com/nrg-raises-67-million-for-a-small-molecule-for-parkinsons-and-als/2026-08-14T13:56:34+01:00https://www.nrgtherapeutics.com/stevenage-uk-based-nrg-therapeutics-raised-a-67m-series-b-today-to-advance-its-aim-to-restore-mitochondrial-function-and-slow-the-progression-of-neurodegenerative-diseases-like-parkinsons-and-als/2026-09-10T10:24:24+01:00https://www.nrgtherapeutics.com/a-british-mitochondrial-startup-wants-to-break-ground-in-als-and-parkinsons-it-has-50m-to-try/2026-08-14T14:16:22+01:00https://www.nrgtherapeutics.com/mitochondria-movers-and-shakers-a-podcast-about-life-with-parkinsons/2026-09-10T10:24:02+01:00https://www.nrgtherapeutics.com/novel-parkinsons-therapy-protects-mitochondrial-function/2026-08-14T14:21:15+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-launches-series-b-after-5m-boost-from-michael-j-fox-foundation/2026-08-14T14:24:06+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-gets-grant-to-test-mitochondria-targeting-als-therapy/2026-08-14T14:27:55+01:00https://www.nrgtherapeutics.com/case-study-life-sciences-future50/2026-09-09T17:40:49+01:00https://www.nrgtherapeutics.com/9-neuroscience-biotech-companies-you-should-know-about/2026-08-14T14:30:32+01:00https://www.nrgtherapeutics.com/mjff-grant-supports-nrg-therapeutics-work-to-validate-mitochondrial-drug-target-for-parkinsons/2026-08-14T14:36:14+01:00https://www.nrgtherapeutics.com/case-study-rd-grant-funding/2026-08-14T14:40:25+01:00https://www.nrgtherapeutics.com/parkinsons-disease-drug-hunters-think-outside-the-%ce%b1-synuclein-box/2026-09-10T10:25:57+01:00https://www.nrgtherapeutics.com/nrg-raises-series-a-funds-for-parkinsons-and-als-therapy-development/2026-08-14T14:44:41+01:00https://www.nrgtherapeutics.com/funding-for-nrg-therapeutics-to-work-on-mitochondria-link-to-parkinsons-and-als/2026-08-14T14:47:07+01:00https://www.nrgtherapeutics.com/nrg-announces-16m-series-a-for-ind-for-parkinsons-and-als/2026-08-14T16:03:58+01:00https://www.nrgtherapeutics.com/following-the-path-to-a-new-drug-together/2026-08-14T16:06:49+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-scores-18m-to-target-mitochondrial-dysfunction-in-parkinsons-als/2026-08-14T16:09:06+01:00https://www.nrgtherapeutics.com/omega-funds-leads-16m-series-a-round-for-nrg-therapeutics/2026-09-10T10:27:34+01:00https://www.nrgtherapeutics.com/nrg-closes-16m-series-a-to-fund-fight-against-neurodegenerative-diseases/2026-08-14T16:11:45+01:00https://www.nrgtherapeutics.com/gsk-vets-theorize-that-a-mitochondrial-target-may-unlock-parkinsons-and-als-treatments-in-new-startup/2026-08-14T16:12:46+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-and-domainex-to-collaborate-on-discovery-of-small-molecules-to-treat-parkinsons-or-motor-neurone-disease/2026-08-14T16:20:20+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-partners-with-domainex-to-develop-neurodegenerative-disease-treatment/2026-08-14T16:21:26+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-selects-domainex-for-project-aimed-at-finding-candidate-for-neurogenerative-disorders/2026-08-14T16:22:31+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-to-develop-small-molecule-disease-modifying-medicines-for-debilitating-chronic-neurodegenerative-disorders/2026-09-10T10:29:34+01:00https://www.nrgtherapeutics.com/2-68m-award-to-nrg-therapeutics-supports-work-into-potential-dmt/2026-08-14T16:27:17+01:00https://www.nrgtherapeutics.com/award-to-help-nrg-therapeutics-develop-new-parkinsons-and-motor-neurone-disease-treatments/2026-08-14T16:28:13+01:00https://www.nrgtherapeutics.com/nrg-receives-2-68m-funding-boost-for-neurodegenerative-disorders/2026-08-14T16:29:17+01:00https://www.nrgtherapeutics.com/sticking-plaster-for-brain-could-beat-parkinsons-disease/2026-09-09T17:41:02+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-awarded-2-68m-to-fight-parkinsons-and-mnd/2026-08-14T16:32:30+01:00https://www.nrgtherapeutics.com/nrg-gearing-up-for-series-a-to-advance-brain-penetrant-ptp-inhibitors/2026-09-09T17:40:56+01:00https://www.nrgtherapeutics.com/parkinsons-uk-takes-investment-in-nrg-therapeutics-to-2-5m/2026-09-10T10:28:37+01:00https://www.nrgtherapeutics.com/cambridge-neuroscience-specialist-nrg-therapeutics-secures-500000-from-the-michael-j-fox-foundation-for-parkinsons-research/2026-08-14T16:35:52+01:00https://www.nrgtherapeutics.com/nrg-therapeutics-wins-500k-from-michael-j-fox-foundation-for-parkinsons-programme/2026-09-10T10:28:46+01:00https://www.nrgtherapeutics.com/my-name5-doddie-foundations-discovery-network-showcase-2026/2026-09-11T14:03:01+01:00https://www.nrgtherapeutics.com/44th-annual-j-p-morgan-healthcare-conference/2026-09-10T12:29:31+01:00https://www.nrgtherapeutics.com/tricals-masterclass-2026/2026-09-10T12:34:59+01:00https://www.nrgtherapeutics.com/ad-pd-2026-advances-in-science-therapy/2026-09-10T12:35:07+01:00https://www.nrgtherapeutics.com/bioeurope-spring/2026-09-10T12:33:51+01:00https://www.nrgtherapeutics.com/neals-workshop-on-advancing-als-clinical-trials/2026-09-10T12:39:15+01:00https://www.nrgtherapeutics.com/target-als-annual-meeting/2026-09-10T12:38:38+01:00https://www.nrgtherapeutics.com/bio-international-convention/2026-09-10T12:40:43+01:00https://www.nrgtherapeutics.com/encals-european-network-to-cure-als-meeting-2026/2026-09-10T12:42:04+01:00